1. Home
  2. CDT vs SBLX Comparison

CDT vs SBLX Comparison

Compare CDT & SBLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • SBLX
  • Stock Information
  • Founded
  • CDT 2019
  • SBLX 2017
  • Country
  • CDT United States
  • SBLX United States
  • Employees
  • CDT N/A
  • SBLX N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • SBLX Telecommunications Equipment
  • Sector
  • CDT Health Care
  • SBLX Consumer Discretionary
  • Exchange
  • CDT Nasdaq
  • SBLX Nasdaq
  • Market Cap
  • CDT 4.2M
  • SBLX 4.0M
  • IPO Year
  • CDT N/A
  • SBLX N/A
  • Fundamental
  • Price
  • CDT $2.84
  • SBLX $4.42
  • Analyst Decision
  • CDT
  • SBLX
  • Analyst Count
  • CDT 0
  • SBLX 0
  • Target Price
  • CDT N/A
  • SBLX N/A
  • AVG Volume (30 Days)
  • CDT 655.2K
  • SBLX 578.8K
  • Earning Date
  • CDT 11-14-2025
  • SBLX 11-11-2025
  • Dividend Yield
  • CDT N/A
  • SBLX N/A
  • EPS Growth
  • CDT N/A
  • SBLX N/A
  • EPS
  • CDT N/A
  • SBLX N/A
  • Revenue
  • CDT N/A
  • SBLX $5,426.00
  • Revenue This Year
  • CDT N/A
  • SBLX N/A
  • Revenue Next Year
  • CDT N/A
  • SBLX N/A
  • P/E Ratio
  • CDT N/A
  • SBLX N/A
  • Revenue Growth
  • CDT N/A
  • SBLX N/A
  • 52 Week Low
  • CDT $2.72
  • SBLX $4.20
  • 52 Week High
  • CDT $2,198.40
  • SBLX $15.28
  • Technical
  • Relative Strength Index (RSI)
  • CDT 57.41
  • SBLX 38.27
  • Support Level
  • CDT $2.78
  • SBLX $4.41
  • Resistance Level
  • CDT $3.22
  • SBLX $4.99
  • Average True Range (ATR)
  • CDT 0.38
  • SBLX 0.60
  • MACD
  • CDT -0.07
  • SBLX -0.07
  • Stochastic Oscillator
  • CDT 6.74
  • SBLX 4.46

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About SBLX StableX Technologies Inc. Common Stock

StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.

Share on Social Networks: